Steve Valentino named VP of Crossmark’s drug division
PLANO, Texas — Crossmark, a sales and marketing company, announced the appointment of Steve Valentino as VP of the company's drug division. He joins Crossmark from Johnson & Johnson, where he led customer development with Walgreens, CVS and Rite Aid on all lines of J&J's business.
"Steve is one of the most respected leaders in the drug channel, bringing more than 25 years of experience and a robust portfolio of relationships,” said Todd Mitchell, president Crossmark sales agency. “He knows how to work with manufacturers and suppliers in developing business solutions that benefit everyone.”
In addition to Valentino, Crossmark's drug team includes Tim Bennett and Alex Yakulis, each of whom bring to the company extensive experience and industry knowledge.
"It’s important to have leaders who not only have strong relationships, but also have deep experience that they can use to help clients drive sales,” Mitchell added. “That’s what Steve, Tim, Alex and the balance of CROSSMARK Drug’s leadership team bring.”
Scotch debuts new clog remover solution
DALLAS — Scotch announced the release of the Instant Power Drain Snake Hair Clog Remover Tool, a chemical-free alternative to unclog drains. The Hair Clog Remover Tool has an 18-in. flexible wand with dozens of “teeth” that grab hair, food, garbage and other obstructions out of a clogged drain.
“With today’s consumer being more environmentally conscious and searching for alternative products to clean and care for their homes, we are offering a chemical-free solution for unclogging drains quickly with our Instant Power Drain Snake Hair Clog Remover Tool,” said Todd Elms, VP marketing.
The Instant Power Drain Snake Hair Clog Remover Tool is now available for distribution through home centers, DIY stores, grocery store chains, drug store chains and mass merchants.
Dr. Reddy’s announces Q1 2015 results
HYDERABAD, India — Dr. Reddy's Labs announced financial results for the quarter ended June 30, which includes consolidated revenues of Rs.35.2 billion, representing year-on-year growth of 24%.
Revenues from the global generics segment came in at Rs.29.0 billion, a year-on-year growth of 32%. Revenues from the pharmaceutical services and active ingredients segment, however, showed a year-on-year decline of 6% at Rs.5.5 billion.
During the quarter, Dr. Reddy's launched 25 new generic products and filed 27 new product applications and 20 DMFs globally.